新型棘白菌素LY303366与两性霉素B和氟康唑相比对临床酵母分离株的体外活性。
In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates.
作者信息
Uzun O, Kocagöz S, Cetinkaya Y, Arikan S, Unal S
机构信息
Department of Medicine, Hacettepe University School of Medicine, Ankara, Turkey.
出版信息
Antimicrob Agents Chemother. 1997 May;41(5):1156-7. doi: 10.1128/AAC.41.5.1156.
Abstract
The in vitro activity of LY303366, a new echinocandin derivative, was evaluated with 191 yeast isolates by a broth microdilution method. The MICs at which 50% of the isolates were inhibited were 0.125 microg/ml for Candida albicans and C. tropicalis, 0.25 microg/ml for C. krusei, C. kefyr, and C. glabrata, and 2.0 microg/ml for C. parapsilosis.
摘要
采用肉汤微量稀释法，用191株酵母分离株对新型棘白菌素衍生物LY303366的体外活性进行了评估。对于白色念珠菌和热带念珠菌，50%的分离株被抑制时的最低抑菌浓度（MIC）为0.125微克/毫升；对于克鲁斯念珠菌、克菲念珠菌和光滑念珠菌，MIC为0.25微克/毫升；对于近平滑念珠菌，MIC为2.0微克/毫升。
相似文献
1
In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates.
Antimicrob Agents Chemother. 1997 May;41(5):1156-7. doi: 10.1128/AAC.41.5.1156.
2
Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.
J Antimicrob Chemother. 2000 Sep;46(3):475-7. doi: 10.1093/jac/46.3.475.
3
Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
Diagn Microbiol Infect Dis. 1998 Sep;32(1):33-7. doi: 10.1016/s0732-8893(98)00050-9.
4
Candida and candidaemia. Susceptibility and epidemiology.
Dan Med J. 2013 Nov;60(11):B4698.
5
Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method.
J Antimicrob Chemother. 2003 Jan;51(1):163-6. doi: 10.1093/jac/dkg018.
6
In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.
J Clin Microbiol. 2005 Nov;43(11):5425-7. doi: 10.1128/JCM.43.11.5425-5427.2005.
7
In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents.
Antimicrob Agents Chemother. 1997 Apr;41(4):763-6. doi: 10.1128/AAC.41.4.763.
8
Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans.
Antimicrob Agents Chemother. 1997 Sep;41(9):1957-60. doi: 10.1128/AAC.41.9.1957.
9
In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital.
Med Mycol. 2005 Mar;43(2):171-8. doi: 10.1080/13693780410001731565.
10
In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species.
Clin Microbiol Infect. 2001 Jan;7(1):11-6. doi: 10.1046/j.1469-0691.2001.00158.x.
引用本文的文献
1
A Rare Case of a Retroperitoneal Abscess Due to Trichosporon spp. in an Immunocompetent Patient.
Cureus. 2024 Mar 6;16(3):e55656. doi: 10.7759/cureus.55656. eCollection 2024 Mar.
2
Trichosporon asahii causing subcutaneous mycoses in an immunocompetent patient: case report and a minireview.
Braz J Microbiol. 2022 Sep;53(3):1221-1229. doi: 10.1007/s42770-022-00737-x. Epub 2022 Apr 5.
3
Candida albicans Infections: a novel porcine wound model to evaluate treatment efficacy.
BMC Microbiol. 2022 Feb 4;22(1):45. doi: 10.1186/s12866-022-02460-x.
4
Deacylation of Echinocandin B by Streptomyces species: a novel method for the production of Echinocandin B nucleus.
3 Biotech. 2019 Nov;9(11):412. doi: 10.1007/s13205-019-1946-7. Epub 2019 Oct 23.
5
Non-healing ulcer due to Trichosporon loubieri in an immunocompetent host and review of published reports.
Mycopathologia. 2013 Aug;176(1-2):107-11. doi: 10.1007/s11046-013-9649-9. Epub 2013 Apr 17.
6
Efficient bioconversion of echinocandin B to its nucleus by overexpression of deacylase genes in different host strains.
Appl Environ Microbiol. 2013 Feb;79(4):1126-33. doi: 10.1128/AEM.02792-12. Epub 2012 Dec 7.
7
Anidulafungin: an evidence-based review of its use in invasive fungal infections.
Core Evid. 2008 Jul 31;2(4):241-9.
8
Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies.
Antimicrob Agents Chemother. 2006 Jan;50(1):143-7. doi: 10.1128/AAC.50.1.143-147.2006.
9
In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.
J Clin Microbiol. 2005 Nov;43(11):5425-7. doi: 10.1128/JCM.43.11.5425-5427.2005.
10
Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis.
Antimicrob Agents Chemother. 2005 Nov;49(11):4795-7. doi: 10.1128/AAC.49.11.4795-4797.2005.
本文引用的文献
1
Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study.
Am J Med. 1996 Aug;101(2):170-6. doi: 10.1016/s0002-9343(96)80072-6.
2
Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1.
Antimicrob Agents Chemother. 1993 Nov;37(11):2449-53. doi: 10.1128/AAC.37.11.2449.
3
A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.
N Engl J Med. 1994 Nov 17;331(20):1325-30. doi: 10.1056/NEJM199411173312001.
4
Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System.
Am J Med. 1991 Sep 16;91(3B):86S-89S. doi: 10.1016/0002-9343(91)90349-3.
5
Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole.
Eur J Clin Microbiol Infect Dis. 1991 Jul;10(7):598-9. doi: 10.1007/BF01967286.
6
Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading.
Antimicrob Agents Chemother. 1991 Aug;35(8):1641-6. doi: 10.1128/AAC.35.8.1641.
7
Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.
N Engl J Med. 1991 Oct 31;325(18):1274-7. doi: 10.1056/NEJM199110313251803.
8
Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review.
Clin Infect Dis. 1992 Mar;14 Suppl 1:S43-53. doi: 10.1093/clinids/14.supplement_1.s43.
Zotero 插件